At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 37 enrolled
Drug / intervention
Cyclosporin A +1 moredrug
Likely dose
Cyclosporin A 3 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase III Study of Recombinant Human Interferon-alpha2a Versus Cyclosporin A for the Treatment of Ocular Behcet's Disease - a National,Randomised, Single-masked Controlled Trial (INCYTOB)
In Brief
A Phase 3 clinical trial evaluating Cyclosporin A and Interferon-alpha2a for Behcet's Disease and 3 related conditions. Completed, enrolled 37 participants across 1 site.
Detailed Summary
The purpose of this study is to investigate if interferon-alpha2a is superior to the standard treatment with cyclosporin A for the treatment of severe ocular manifestations of Behcet's disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBehcet's Disease, Panuveitis, Posterior Uveitis, Retinal Vasculitis
CountriesGermany
Collaborators--
Timeline
Phase 3CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2004
First PostedSep 2005
Primary CompletionDec 2014
TodayJul 2026
First PostedSep 14, 2005
Enrollment StartNov 1, 2004
Primary CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 10.1 yearsPosted 20.8 years ago
Interventions
Cyclosporin Adrug
3 mg/kg bw, augmented to 5 mg if necessary and combined with prednisolone. Adapted to serum levels
Interferon-alpha2adrug
3-6 million iU per day sc., augmented to up to 9 if necessary, later reduced (according to clinical response) to 3 x 3 million iU /week.